Clinical trials – XENOTHERA

Home
-
Clinical trials

~~clinical trials~~

Several clinical trials ongoing

Our policy is to allow any volunteering patient to participate in our clinical trials, if eligible. Do not hesitate to contact us for more information.

FIPO 23

FIPO23 (NCT06154291) is a Phase I/II, Multi Center, Open Label, First-in-human, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-tumors Efficacy of the Glyco-humanized Polyclonal Antibody XON7 in Patients With Advanced or Metastatic Solid Tumors. This is a two-stage trial consisting of a Part I, dose escalation and dose-finding component to establish the Maximal Tolerated Dose (MTD), if any, and Recommended Part 2 Dose (RP2D) of XON7, followed by a Part II component to investigate anti-tumors efficacy in selected solid tumor types and to further evaluate safety and tolerability of XON7 at RP2D. The trial is currently recruiting in France and Belgium.

PALT 1

PALT1 is a Phase I/II, open-label, multi-center study to evaluate the safety and efficacy of glyco-humanized polyclonal antibody directed against tumoral T cells, in patients with relapsed/refractory peripheral T cells lymphoma (PTCL).

Euroxav and Polycor

Euroxav (NCT04928430) and Polycor (NCT04453384) are the two clinical trials held to evaluate the efficacy and safety of XAV19 in patients with mild, moderate or severe COVID19. They are both completed or stopped. The efficacy of XAV19 in accelerating the recovery for patients was highly significant. Data are available on MedRxiv.

LIS 1

LIS1 (NCT04431219 ) is a First in Human Study for the Assessment of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Multiple Ascending Intravenous Doses of LIS1 in Kidney Transplanted Patients. It was held in Czeck Republic and was completed in 2022. The pharmacodynamic and safety endpoints were reached, and the confirmatory trial is planned in the coming year.